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1. Introduction 
In a population of 1 million inhabitants, 2400 patients will have a stroke every year, of 
whom fewer than 50% will be independent 1 year later (Hankey & Warlow, 1999). Many 
independent survivors have residual physical or cognitive deficits, or behavioural changes 
which can affect family life and have professional consequences (Leys et al. 2002). Post 
Stroke Dementia (PSD), that includes any dementia after stroke, irrespective of its cause, is 
therefore a clinical syndrome – and not a disease – and it appears to be one of the main 
causes of dependency in stroke survivors.  
An huge increase in prevalence and burden of PSD is likely to happen (Mackowiak-
Cordolani et al. 2005) because of the decline in mortality after stroke (Rothwell et al. 2004) 
and ageing of populations. 
Therefore, stroke has been found to be a strong predictor of dementia. This association is 
present both for clinically apparent strokes as well as for subclinical strokes. More than 25% 
of patients develop dementia after their first or recurrent stroke. The prevalence is slightly 
lower when patients with pre stroke cognitive impairment are excluded. On the other hand, 
the diagnosis of vascular dementia (VaD) remains a controversial issue in many aspects and 
concepts. These nosologic problems are caused both by the methods, insufficient to ascertain 
the diagnosis, as well as by the weak consistency of the clinical concept of VaD itself. VaD is 
defined as a combination of clinical and neuropathological manifestations characterized by 
dementia in association with variegated brain lesions of vascular or circulatory origin 
(Ferrer, 2010); PSD obviously includes all cases of VaD but also these cases where stroke 
adds to an already clinically evident neurodegenerative cognitive impairment. One of the 
most intriguing issues on VaD, and in particular on PSD, is related to the time of 
development of cognitive decline. 
In clinical practice, the 3-month time threshold is usually chosen to enable resolution of a 
possible acute post-stroke delirium, and to obtain a more reliable cognitive assessment with 
a complete regression of acute neuropsychological stroke-related deficits. As a matter of 
fact, it has been found that most cognitive impairments after stroke, in particular visual 
memory and visuospatial construction, resolve beyond the subacute time period. Moreover, 
as the time after stroke increases, so does the likelihood that an individual might have other 






The time course of PSD is strictly related to its pathophysiology: it may be 1) the direct 
consequence of a vascular lesion; 2) due to the additive effect of recurrent strokes and white 
matter lesions; 3) the result of pre-existing neuropathological Alzheimer’s Disease (AD) or 
similar neurodegenerative dementias, such as Lewy Body Dementia (LBD) or Fronto-
Temporal Dementia (FTD). Concerning these neurodegenerative conditions, it is not clear if 
the effect of stroke on dementia is due to a direct increase in neuropathological changes 
associated with AD-LBD-FTD, or to the synergic effect of AD-LBD-FTD pathology and 
vascular pathology. 
Another relevant issue is the possibility to predict which patient will develop PSD. In this 
regard, recent data indicate an overlap between AD-LBD-FTD and PSD, which seems to 
share risk factors and neuropathology. In most population samples these disorders appear 
together, and the consensus is growing that a degenerative component has a more 
important role in determining PSD onset shortly after stroke than previously recognized. 
Therefore, anamnestic data have a fundamental role in this prognostic approach. 
In this chapter, the authors try to clarify the “mystery” of the time onset of PSD. They will 
start with an overview concerning the new pathogenetic determinants of PSD. Later, they 
will attempt to offer a systematic analysis of the amount of data concerning PSD itself. PSD 
and its onset time really are a dilemma; aim of this chapter is to suggest a new potential 
approach to make clarity in this puzzled question. 
2. Timing of Vascular Dementia (VaD) and Post Stroke Dementia (PSD) 
One of the most intriguing issues on VaD, and in particular on PSD, is the time course of the 
development of cognitive decline. In other words, what is the “correct” timing to define 
“demented” a stroke patient? Tatemichi 21 years ago was the first to put VaD in a temporal 
context, by observing that 3 months after stroke about one fourth of the patients developed 
PSD (Tatemichi et al., 1990). Several subsequent studies confirmed this finding, so the time 
relationship between stroke and cognitive decline was included in the diagnostic criteria for 
VaD.  
Nevertheless, this time interval has been variously faced by different diagnostic criteria. In 
the ADDTC criteria the diagnosis of ischemic vascular dementia is “probable” when in 
addition to dementia there is “evidence of two or more ischemic strokes by history, 
neurologic signs, and/or a single stroke with a clearly documented temporal relationship to 
the onset of dementia” (Chui et al., 1992). 
In the NINDS–AIREN criteria the relationship between stroke and dementia is “within 3 
months after a recognized stroke”; however, this time relationship is not mandatory. In fact, 
a diagnosis of VaD is also probable when a patient presents “abrupt deterioration of 
cognitive functions after stroke or fluctuating, stepwise progression of cognitive deficits” 
(Roman et al., 1993). In the ICD-10 criteria for VaD, subdivided into ethiologic subtypes, 
VaD with acute onset is a dementia developing rapidly (i.e. usually within 1 but no longer 
than 3 months) after a succession of strokes, or (rarely) after a single large infarction. The 
diagnosis of VaD due to multi-infarcts is even more vague, being the onset of dementia 
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In clinical practice, the 3-month time threshold is usually chosen to enable resolution of a 
possible acute post-stroke delirium and to obtain a more reliable cognitive assessment with 
a complete regression of acute neuropsychological stroke-related deficits. On the other 
hand, about 50% of acute stroke patients may show some improvement in global cognition 
up to 1 year after stroke (Ballard et al., 2003). Long-term improvement in generalized 
cognitive function seems to occur more frequently in patients who have experienced left 
hemisphere infarctions or very severe hemispheric stroke syndromes. 
On the contrary, diabetes mellitus seems to compromise the ability to achieve long-term 
improvement in cognitive function after stroke, both ischemic and hemorrhagic, suggesting 
that management of this important vascular risk factor should be performed with care and 
consistency (Desmond et al., 1996; Tham et al., 2002). Recent data show evidence for an 
overlap between Alzheimer's disease (AD) and PSD, which appear to share risk factors and 
neuropathology (Snowdon et al., 1997; O'Brien et al., 2003). Whether the relationship 
between AD and PSD in determining cognitive decline is “additive” or due to a “cause–
effect” mechanism remains to be determined. In most population samples, these two 
disorders appear together, and the consensus is growing that a degenerative component has 
a more important role in determining the PSD onset shortly after stroke than previously 
recognized (Roman & Royall, 2004; Rockwood et al., 1999). Substantial data indicate that 
comorbid ischemic cerebrovascular disease may contribute to convert patients with 
“preclinical AD” to a clinical form, thus unmasking, and anticipating, a previous 
pathological process (de la Torre, 2002). 
What is said for AD probably is true for the other degenerative dementias as well, therefore 
in this Chapter we will use the definition of AD-LBD-FTD to indicate the main group of 
these neurodegenerative processes. Clinicians rarely diagnose AD until pathology has 
reached the cortical regions related to executive functions (Royall, 2002). If executive 
impairment caused by sub-cortical vascular disease is superimposed on AD pathology, then 
clinical AD is likely to be diagnosed earlier (Roman & Royall, 2004). 
In this view, the occurrence of a new vascular lesion might unbalance a previous 
equilibrium thus revealing a “clinical” dementia syndrome. Therefore, anamnestic data have 
a fundamental role in the prognostic approach. Clinically, previous cognitive status and 
post-stroke delirium show an important correlation with the future development of PSD 
(Rothwell et al., 2005; Henon et al., 1999). Anatomical location of the lesion and its volume 
are also important (Gold et al., 2005). All the other risk factors for VaD and for stroke show a 
correlation, but this is probably due to the chance of new vascular events, including the 
silent strokes (Vermeer et al., 2003). Whether PSD represents the same clinical and 
pathological entity from the early phase up to the following years remains to be determined.  
2.1 Post Stroke Dementia: A misleading definition 
The comprehension of the pathophysiological phenomena influencing the time onset of 
cognitive decline after stroke is very complex, and involves researchers in different fields, 
such as pathologists, neuroradiologists, molecular biologists and physicians. 
The term PSD includes all kinds of dementia developing after stroke, independently of the 
intrinsic features of the stroke itself. This term is probably become outdated, because its 






be responsible of the cognitive impairment and, subsequently, of dementia. Now, data show 
that this is a quite uncommon eventuality 
In fact, in the largest number of cases, the occurrence of stroke seems to be only the clinical 
sign of an underlying vessels’ disease. Nevertheless, it has been suggested that this vessels‘ 
disease could have a key role in the pathogenesis of vascular and neurodegenerative 
dementias. 
Perhaps, VaD and sporadic AD-LBD-FTD could have a common origin, like a vascular 
disorder that affects the vessel wall (particularly the two inner layers), and that may have a 
wide range of clinical presentations. This heterogeneity is probably related to genetic 
differences between individuals; in fact, the genotypic variety allows the existence of 
different phenotypes. Because of those aforementioned concepts, epidemiological studies 
are not designed with uniform criteria (Pendlebury, 2009), since it is difficult to create a 
consensus concerning which kind of demented stroke patient deserves to be enrolled. In 
addition, many factors can influence the prevalence and incidence of PSD such as: the mean 
age of the study population, the exclusion or not of patients with aphasia or severe physical 
disability, the mortality rates, the delay between stroke onset and the cognitive assessment, 
the criteria used for the diagnosis of dementia, the presence of a previous cognitive 
impairment or dementia (Pendlebury, 2009). 
Currently, we can safely affirm that: 1) the occurrence of stroke doubles the risk of PSD; 2) 
the attributable risk is the highest within the first year after stroke, then declines, while the 
relative risk of dementia remains stable around 2; 3) the risk of delayed dementia, including 
Alzheimer’s disease (AD) and the other neurodegenerative dementias (LBD, FTD), also 
remains doubled 10 years and more after stroke. Researchers tried to fill this knowledge gap 
through the identification of the cause-effect relationship between specific pathological 
conditions and PSD. In particular, considerable efforts have been made in the attempt of 
understanding the role of specific cardiovascular risk factors determining PSD itself. In the 
Authors’ opinion, the basic issues of this intense research activity are five, at least. They are: 
1) What are the pathophysiological mechanisms of PSD?; 2) What are the risk factors more 
related to the development of PSD? 3) And which of them are more related to time onset of 
PSD? 4) Is it possible to create homogeneous groups of patients in order to perform a risk 
stratification of PSD? 5) Would it be possible to create a risk stratification also with regard to 
the time onset of PSD? 
Obviously, it seems almost superfluous to say that no one has been able to give a satisfying 
answer to these fundamental questions. Until now, at least. However, it is precisely from 
these facts, apparently in conflict with each other, that we can draw the starting point not 
only to give a unified view of PSD, but also to explain the dilemma related to its onset time. 
2.1.1 Role of risk factors 
Currently, the state of affairs is quite garbled and there are no definitive data on this topic. 
However, scientific evidence allowed to set aside the idea that PSD is just the result of the 
occurrence of stroke. In fact, if the acute cerebrovascular event was the only responsible for 
the development of cognitive impairment, we would not be able to explain why not all 
stroke patients develop PSD. 
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In addition, we would not even have any plausible elucidation for the different time of onset 
of dementia in some patients than in others. Reported risk factors for pre- and post-stroke 
dementia are not always consistent between studies, probably owing to small sample sizes. 
To overcome this problem, available data was combined in a meta-analysis to attempt to 
determine the most significant factors involved in the development of PSD (Pendlebury et 
al., 2009). 
All but one study addressed to the risk factors associated with pre-stroke dementia include 
patients with first ever and with recurrent stroke, so many of the patients will have had a 
past history of stroke. Patients with pre-stroke dementia are significantly older (weighted 
mean difference = 9.1, 8.4–9.8 years p < 0.0001) than those without pre-stroke dementia. 
Rates are also significantly higher in women and in those with little education, and in 
patients with medial temporal lobe atrophy, family history of dementia, previous stroke or 
TIA, leukoaraiosis, multiple infarcts, diabetes, atrial fibrillation, hypertension, and global 
cerebral atrophy (Pendlebury et al., 2009). Post-stroke dementia, like pre-stroke dementia, is 
associated with older age (weighted mean difference = 5.1, 4.6–5.7, years p < 0.0001) and low 
educational attainment, and also prior cognitive decline and premorbid disability 
(Pendelbury et al., 2009). 
Associated vascular risk factors include diabetes and atrial fibrillation but not hypertension, 
ischemic heart disease, cholesterol, prior TIA or smoking. However, the majority of factors 
associated with post-stroke dementia are related to the stroke itself, and include 
hemorrhagic stroke, left hemisphere stroke, dysphasia, stroke severity, infarct volume, and 
the presence of multiple strokes separated in space and time (previous stroke, multiple 
infarcts, and recurrent stroke). Certain complications of stroke including incontinence, early 
seizures, acute confusion, hypoxic ischemic episodes and hypotension are also strongly 
associated with post-stroke dementia. 
Being Caucasian is protective in comparison to black or Hispanic. It is unlikely that all the 
factors listed in are independent predictors of post-stroke dementia. Non-stroke-related risk 
factors that tend to remain significantly predictive of post-stroke dementia in multivariate 
analyses are age, low educational attainment, diabetes, atrial fibrillation, and leukoaraiosis 
(Pendlebury et al., 2009). 
Therefore, although these risk factors are statistically independent, they could still be 
confounded by stroke-related factors. For example, atrial fibrillation and diabetes are 
associated with symptomatic stroke, asymptomatic stroke on imaging, recurrent stroke, 
multiple stroke lesions, and severity of stroke; and leukoaraiosis is associated with stroke 
severity and stroke recurrence. The factors associated with pre-stroke dementia are broadly 
similar to those for post-stroke dementia, perhaps unsurprisingly, since all but one study on 
the predictors of pre-stroke dementia include patients with recurrent as well as first-ever 
stroke. In pre-neuroimaging era, Fazio and Loeb frequently affirmed that in the past history 
of demented patients, the occurrence of TIAs was more frequent that in the general 
population. Medial temporal lobe atrophy, female sex and family history of dementia are 
much stronger predictors of pre- than post-stroke dementia, suggesting a more important 
role for primary degenerative pathology in pre-stroke dementia. Interestingly, hypertension, 
ischemic heart disease and prior TIA were associated with pre- but not post-stroke 
dementia. The fact that hypertension was not associated with post-stroke dementia may also 






without post-stroke dementia. Atrial fibrillation is associated with both pre- and post-stroke 
dementia, presumably since its prevalence increases with age, and it is linked to multiple 
and recurrent strokes and increased stroke severity. There is also some evidence that atrial 
fibrillation is associated with cognitive impairment and hippocampal atrophy in the absence 
of symptomatic stroke or even silent infarction (Ott, 1997; Knecht, 2008). Diabetes is a 
known risk factor for dementia and mild cognitive impairment and is associated with both 
pre- and post-stroke dementia. In addition to age-related physiological decline, diabetes 
disturbs microvascular functions through mechanisms including activation of protein kinase 
C, excess production of reactive oxygen species and cellular activation of the receptor for 
advanced glycation endproducts (RAGE). Further, animal studies show that diabetes 
exacerbates post-stroke brain damage (Zhang et al., 2009) and there is evidence that diabetes 
is associated with reduced recovery of cognitive function after stroke (Nys et al., 2005).  
As a matter of fact, it is difficult to give an accurate image of the role that every risk factor 
could have in the pathogenesis of PSD. This syndrome seems to be a real complex 
phenomenon, and each of them could probably determine PSD with a power that is 
different for every patient. 
In conclusion, stroke could be the acute event that reveals an underlying cognitive 
impairment. Probably, it would be essential to read between the lines, understanding the 
limits of research and the restricted margins of our classifications criteria. In the future, 
scientific evidences will maybe force us to give a new interpretation of these elements, that 
could be viewed like various components of the same pathological process.  
Four major determinants deserve to be mentioned, in order to better clarify what it has been 
said. They are: 1) demographic and medical characteristics of the patient with PSD and their 
influence on stroke outcome, 2) neuroimaging characteristics, 3) stroke characteristics, 4) 
pre-existing pathological alterations. (Pendelbury et al., 2009). 
These elements are crucial for the understanding of the most accredited theories about the 
ethiology of PSD, but especially to recognize the state of knowledge on its onset time.  
2.1.2 Demographic and medical characteristics of the patient with PSD and their 
influence on stroke outcome 
The most important demographic predictors of dementia after stroke, in sufficiently 
powered studies, are increasing age and low education level, but not gender, when the 
analysis is adjusted for age (Zhu et al., 2000). 
The risk of dementia after stroke is higher in patients who were already dependent before 
stroke (Zhu et al., 2000). Pre-stroke cognitive decline without dementia, assessed by 
standardized questionnaires, is obviously associated with a higher risk of dementia after 
stroke (Zhu et al., 2000; Snowdon et al., 1997). 
Diabetes mellitus, atrial fibrillation and myocardial infarction were also independent risk 
factors for dementia after stroke in several studies. (Zhu et al., 2000). Arterial hypertension, 
a risk factor for VaD and AD, has not been clearly identified as a risk factor for PSD. 
Epileptic seizures (Esiri et al., 1999), sepsis, cardiac arrhythmias and congestive heart failure 
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However, the statistical relationship found between these disorders and dementia does not 
mean a causal relationship: it is also possible that dementia increases the risk of such events 
(Zhu et al., 2000). The influence of hyperlipidemia, hyperhomocysteinemia, alcohol 
consumption and cigarette smoking on dementia after stroke remains unproven (Zhu et al., 
2000). The results concerning cigarette smoking should be interpreted with caution, because 
smoking influences mortality and stroke recurrence. ApoE4 genotype is associated with an 
increased risk of dementia after stroke (de la Torre, 2002). 
The most common causes of PSD are VaD, AD-BLD-FTD and mixed dementia (Leys et .al., 
2005). AD-BLD-FTD, mixed AD-BLD-FTD and VaD account for 19-61% of patients with 
PSD. Vascular lesions have a prominent role in the development of PSD in the following 
circumstances: patients with stroke who are too young to have AD-BLD-FTD, and who have 
dementia just after stroke; when cognitive functions were normal before stroke, impaired 
immediately after, and did not worsen or improve over time; when a specific vascular 
condition known to cause stroke and dementia is proven by a specific marker; and when the 
lesion is located in a strategic area (Alexander & Freedman, 1984; Benson & Cummings, 
1982; Bhatia & Marsden, 1994; Ott & Saver, 1993). 
Even when vascular lesions, Alzheimer’s pathology and white matter changes do not lead to 
dementia by themselves, their cumulative effect can reach the threshold of lesions required 
to produce dementia (Pasquier & Leys, 1997); as well as when stroke, white matter changes, 
or both, occur in a patient with asymptomatic Alzheimer’s pathology, the period of 
preclinical AD might be shortened (Pasquier & Leys, 1997). This hypothesis is supported by 
the results of several studies. In the Optima and in the Nun studies, among patients who 
met neuropathological criteria for AD, those with brain infarcts had poorer cognitive 
functions and a higher prevalence of dementia (Nagy et al., 1997; Snowdon et al., 1997). In 
the dementia substudy of the Systolic Hypertension in Europe Trial (SYST-EUR), 
nitrendipine decreased the incidence rate of stroke and AD (Forette et al., 1998), suggesting 
that stroke prevention reduces the risk of new-onset AD; previous cognitive decline and no 
dementia, likely to be degenerative in origin in most patients (Henon et al., 1995), is a risk 
factor for PSD (Henon et al., 2001). Most patients with previous cognitive decline and no 
dementia who developed PSD have a clinical presentation of AD, but it occurs months after 
a stroke. 
The concept of mixed dementia might be useful for those patients because it emphasizes 
that these patients should be treated for AD but should also receive an appropriate therapy 
to prevent stroke. Treatment of these patients as thought they have AD, even if the time-
course suggests AD, may make practitioners ignore the vascular component that is treatable, 
especially if the stroke occurs years before. 
Moreover, both population-based studies (Aevarsson et al., 1995; Baldereschi et al., 1999; 
Woo et al., 1992; Tatemichi et al., 1994) and hospital based (Roth, 1955) studies have shown 
that patients with PSD have higher mortality rates than patients without dementia, 
independent of age and comorbidities (Aevarsson et al., 1995). The long term mortality rate 
is two to six times higher in patients with PSD, after adjustement for demographic factors, 
associated cardiac diseases, stroke severity and stroke recurrence (Desmond et al., 2002; 
Henon et al., 2003; Tatemichi et al., 1994). In patients with pre-existing dementia, mortality 






mortality among patients with PSD might be the result of several factors; 1) patients with 
dementia of any cause have high mortality (Helmer et al., 2001); 2) Stroke mortality may be 
high in patients with dementia (Helmer et al., 2001); 3) Dementia is associated with more 
severe vascular diseases and a higher risk of complications (Tatemichi et al., 1994); 4) 
Dementia may worsen co-occuring disorders; patients with dementia may receive less 
aggressive stroke prevention (Rockwood et al., 1997; Gurwitz et al., 1997), and less 
appropriate treatment of associate disorders (Krumholz et al., 1996) although causes of 
death can be similar in patients with and without PSD and management was similar for 
both groups in the Lille Study (Barba et al., 2002; Henon et al., 2003); 5) Patients with PSD 
may be less compliant to treatments necessary for stroke prevention (i.e. antithrombotic 
agents and treatment of vascular risk factors), which could lead to less effective prevention 
of new vascular events and a higher mortality rate. Furthermore, the New York study 
(Moroney et al., 1997) has demonstrated that dementia diagnosed 3 months after stroke was 
associated with a three times greater increased risk of stroke recurrence (relative risk: 2.71; 
95% CI 1.36 – 5.42). 
Dementia might be a marker for a more severe vascular disease leading to an increased risk 
of recurrence, but also an indicator of a less intensive stroke prevention and lack of 
compliance that can contribute to the increased risk of recurrence (Moroney et al., 1997). 
White matter changes could also be a confounding factor because they are associated with 
an increased risk of stroke recurrence (Henon et al., 2001). 
In addition, the few data on the influence of PSD on functional outcome suggest that 
patients with PSD are more impaired and more dependent in daily living activities than 
patients with stroke who do not develop PSD (Tatemichi et al., 1990; Tatemichi et al., 1992; 
Barba et al., 2000; Lin et al., 2003; Prencipe et al., 1997). 
In conclusions, many efforts have been made to define which kind of patient is at increased 
risk of PSD, but there are no definitive data. For the majority of the patients, the occurrence 
of stroke is only the clinical expression of a just advanced pathological process, which affect 
the brain and will lead to the loss of cognitive functions. 
In this context, time of onset of PSD is strictly related to the pre-stroke conditions of the 
patient’s brain. Actually, all the evidences confirm that dementia will occur more rapidly in 
individuals with the worst cognitive and clinical status. The strict connection between 
cardiovascular risk factors and PSD and the overlapping between VaD, particularly PSD, 
and AD-BLD-FTD, corroborate the hypothesis about the existence of a common 
pathogenetic mechanism (a vessel’s wall disease), responsible not only for the pathogenesis 
of the classical “cardiovascular” risk factors, but also for a chronic brain hypoperfusion, 
which could cause/increase/accelerate the neurodegeneration of specific genetically 
predisposed neuronal populations and represent the starting point for VaD.  
Obviously, the matter is quite complex, and there are no definitive data. This happens for 
many reasons, mainly related to the differences in inclusion criteria for subjects enrolled in 
clinical trials. We must also remember that all involved variables, particularly 
cardiovascular risk factors, have a wide range of clinical presentations between individuals, 
with a degree of complexity that is difficult to describe with a statistical program. So, it is 
very difficult to define the correct role that each of them could have in causing the 
occurrence of PSD and its onset time. 
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Later, the authors will attempt to clarify these concepts, starting from the assumption that 
every risk factor should not be considered independently from the others, but that each of 
them can be considered the epiphenomenon of the abovementioned underlying vascular 
disease. This perspective is of considerable relevance, because it allows a unique view of the 
heterogeneous landscape described in this chapter.  
2.1.3 Neuroimaging charateristics  
To our best knowledge, there is no study with functional neuroimaging techniques such a 
SPECT, PET, functional MRI, or spectroscopy, addressed to identify predictors of PSD in 
large series of consecutive patients with stroke. Functional neuroimaging studies have 
provided a useful conceptual framework for the understanding of VaD, but were not 
addressed to PSD. Plain neuroimaging has shown the frequent occurrence of silent infarcts, 
that is cerebral infarcts seen on CT or MRI scans that have never been associated with a 
corresponding neurological deficit. One study found no relation between silent infarcts and 
PSD (Bornstein et al. 1996), but the assessment of the pre-existing cognitive status was not 
standardized, and the study was underpowered. Other studies clearly identified silent 
infarcts as independent predictors of PSD (Tatemichi et al., 1990; Desmond et al., 2000; 
Henon et al., 2001; Pohjasvaara et al., 2000). 
The influence of silent infarcts is more important when the delay between stroke and 
cognitive assessment is longer. In the Lille study, silent infarcts were associated with PSD in 
the third year but not in the second (Corea et al., 2001), and in the Maastricht study silent 
infarcts were independently related to dementia after 1 year, but not after 1 month or 6 
months (Rasquin et al., 2004). 
Global cerebral atrophy is associated with a higher risk of PSD (Linden et al., 2004; 
Desmond et al., 2000; Tang et al., 2004; Altieri et al., 2004; Ivan et al., 2004; Tatemichi et al., 
1993). 
Medial temporal lobe atrophy (MTLA) is most common in patients with stroke who have 
preexisting dementia (Henon H et al., 1998), but it can also be present in patients with stroke 
and no dementia. In the Lille study the cumulative proportion of 3-year survivors free of 
dementia was significantly lower in patients with MLTA (57.6% vs 80.8%) (Cordoliani-
Mackowak et al., 2003). 
MLTA clearly differentiates patients with dementia from those who do not have dementia 
after a first-ever ischaemic stroke, even after exclusion of patients who have pre-stroke 
cognitive impairment (Pohjasvaara et al., 2000; Ballard et al., 2003). Patients with stroke with 
MLTA might have a pre-clinical AD, which is clinically revealed by stroke (Pasquier & Leys, 
1997). However, MLTA is not specific to AD, as it has also been observed in VaD (Jobst et 
al., 1998; Fein et al., 2000). In elderly patients with stroke and no dementia (with moderate to 
severe MLTA) after adjusting for age, volume of infarcts and cortical atrophy, do notably 
worse in tests of learning, story recall, visual reproduction, block design, and mental speed 
(Jokinen et al., 2004), suggesting that, in elderly patients who have stroke but no dementia, 
MLTA is associated with poor memory and visuo-spatial functions, whereas verbal and 






Presence and severity of white matter changes are independent predictors of PSD (Tang et 
al., 2004). However, there are major potential confounding factors: cerebral atrophy, which 
is more frequent in patients with white matter changes; lacunar infarcts, which share a 
common pathogenesis with white matter changes than those with stroke alone (Tatemichi et 
al., 1990; Pasquier & Leys, 1997). In a study to determine the neuroimaging correlates of 
cognitive ability in patients with lacunar infarcts, left frontal lobe atrophy and presence of 
thalamic infarct were independent predictors of worse cognitive performances (Mok et al., 
2005). 
Finally, silent infarcts, global cerebral atrophy, medial temporal lobe atrophy and white 
matter changes are predictors of PSD. There might be a lot of reasons to explain the 
inconsistency of data listed before: in particular the heterogeneity and the confusion of the 
selection criteria; the study samples not uniform. The simple occurrence of stroke cannot 
represent a crystal clear inclusion criteria. Every stroke is different than others, because 
there are many discrepancies in the basal conditions of the patient, in the etiology, in the 
pathogenesis and in the further mechanisms and evolution of stroke itself. 
Moreover, following the “vessels disease” theory, stroke and atherosclerosis are not the 
disease, but only an epiphenomenon of a more complex matter. In addition, PSD occur more 
rapidly in those patients with a larger number of brain injuries, independently from their 
nature (vascular or neurodegenerative). Obviously, the aforementioned vessels’ wall disease 
is not demonstrable with current neuroimaging techniques, because our detection tools 
allow only the identification of the consequences that this pathology produces on patients’ 
brain, like strokes, silent and micro-infarcts, small vessels disease (cortical and sub-cortical), 
and cerebral atrophy. In the last years, TC-PET and SPECT have achieved a key role in the 
early diagnosis of Mild Cognitive Impairment (MCI) and AD-LBD-FTD. TC-PET and SPECT 
are perfusion techniques, at first. So, a chronic hypoperfusion in the early stages of AD-LBD-
FTD has been demonstrated (Liu et al, 2011; de La Torre, 2010; Pakrasi & O’Brien, 2005). 
Consequently, you can not only suggest a possible role of chronic hypoperfusion in 
determining AD-LBD-FTD, but also suppose that new technologies could allow innovative 
and surprising findings concerning this fascinating issue, in the next future.  
2.1.4 Stroke characteristics 
Most studies found that a more severe clinical deficit at the onset of stroke is associated with 
a higher risk of PSD (Tatemichi et al., 1990; Desmond et al., 2000; Henon et al., 2001; 
Pohjasvaara et al., 1997). Studies that did not find this association (Kolmen et al., 1996; 
Altieri et al., 2004; Desmond et al., 2002), are characterized by high mortality rates in 
patients with severe deficits that may have created recruitment bias (because of a short 
delay between stroke onset and recruitment). 
The risk of PSD and its severity are not influenced by the type of stroke (ischemic or 
hemorrhagic) (Linden et al., 2004; Pohjasvaara et al., 1998; Barba et al., 2000; Henon et al., 
2001; Madureira et al., 2001; Rasquin et al., 2004). However, differences in survival rates 
between stroke subtypes are making the results difficult to interpret. 
In the Framingham study large artery infarcts, lacunar infarcts and infarcts of unknown 
origin were associated with a higher risk of PSD than cardioembolic infarcts (Ivan et al., 
2004). In other studies, the risk of PSD was lower in patients with small vessel occlusion 
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than in patients with large arterial stroke (Tatemichi et al., 1990; Desmond et al., 2000; Mok 
et al., 2004; Rasquin et al., 2004). Accordingly, a study evaluating stroke volumes showed a 
relationship between higher stroke volume and the risk of dementia (Sachdev & Brodaty, 
1999). 
However, all these results are influenced by the higher mortality rate in stroke subtypes 
associated with more severe deficits, in patients who are the most likely to develop PSD 
when they survive. Supratentorial lesions, left hemispheric lesions, anterior and posterior 
cerebral artery territory infarcts, multiple infarcts and so-called “strategic infarcts”, i.e. 
cerebral infarcts that may lead to dementia on their own in the absence of any other lesion, 
have been found to be associated with an increased risk of dementia after stroke in at least 
two independent studies (Leys et al., 2005). However, strategic locations (left angular gyrus, 
inferomesial temporal and mesiofrontal locations, thalami, left capsular genu, caudate 
nuclei) were described more than 20 years ago, in single case reports, or in small series, 
usually without MRI, and without follow-up (Leys et al., 2005). Other vascular brain lesions 
interfering with the neuropsychological deficit cannot be excluded in the absence of MRI 
(Leys et al., 2005), and coexisting AD-LBD-FTD cannot be excluded in absence of follow-up 
(Leys et al., 2005). Therefore, the concept of strategic stroke should be revisited with large 
prospective studies, with MRI scans to exclude associate lesions, and a follow-up long 
enough to exclude associated AD-BLD-FTD (Leys et al., 2005). In conclusion, stroke itself is 
rarely the only responsible of PSD. The clinical experience and scientific data show that the 
occurrence of a “strategic” or “large” brain infarct is an unfrequent event. Only in these 
cases, in fact, the stroke could cause deterioration of patients’ cognitive functions and 
subsequent PSD. As the authors said in the previous paragraphs of this chapter, stroke 
should be considered as the clinical expression of an underlying vascular disease, that could 
cause dementia through the synergistic and addictive effect of a large number of clinically 
unrevealed brain injuries. Stroke itself would be only able to anticipate the timing of 
dementia. However, stroke would not be the disease, but only one of its clinical signs. These 
concepts are supported by several data; in fact, apart from the previous cited strategic 
locations, PSD most likely occurs in patients with a “more severe clinical deficit at onset”. 
The term “More severe clinical deficit” means the presence of a large number of previous 
brain injuries (vascular or neurodegenerative), together with a worse clinical condition, 
caused by a poorer detection and control of classical cardiovascular risk factors 
(hypercholesterolemia, diabetes, hypertension, heart failure and so on). In both of cases, the 
clinical landscape is dominated by the vascular disease, which is the responsible not only for 
the accumulation of these chronic damages, but also of the occurrence of stroke. Therefore, 
stroke is simply an epiphenomenon, that contributes to anticipate or to reveal an earlier 
cognitive impairment, causing PSD, which merely is another consequence of this complex 
pathological process. As matter of fact, it is not easy to predict which kind of stroke patient 
will develop dementia before from the others. Certainly, the onset of PSD will be more rapid 
in those patients with the worst degree of clinical and cerebral involvement. 
2.1.5 Pre-existing brain lesions in stroke patients 
Silent infarcts, i.e. cerebral infarcts seen on CT or MRI scans that have never been associated 
with a relevant neurological deficit, are associated with an increased risk of dementia after 






Their influence seems to increase according to the duration of the follow-up: in the Lille 
study, silent infarcts were associated with dementia after stroke at year 3 but (Henon et al., 
2001) not at year 2, and in the Maastricht study silent infarcts were independently related to 
dementia after 12 months, but not after 1 or 6 months (Rasquin et al., 2004). 
Stroke patients with associated previous silent infarcts seem to have a steeper decline in 
cognitive function than those without, but this decline might be confined to those with 
additional silent infarcts after base-line. Global cerebral atrophy is associated with a higher 
risk of dementia after stroke (Leys et al., 2005). MTLA is more frequent in stroke patients 
who have pre-existing dementia but it may also be present in non-demented stroke patients. 
MTLA clearly differentiates demented from non-demented patients after a first-ever 
ischemic stroke, even after exclusion of patients who had pre-stroke cognitive impairment 
(Leys et al., 2005). 
Stroke patients with MTLA may have pre-clinical AD-BLD-FTD that is clinically revealed by 
stroke (Leys et al., 2005; Pasquier & Leys, 1997; Firbank et al., 2007). However, MTLA is not 
specific for AD-BLD-FTD, as it has also been observed in VaD (Leys et al., 2005). The 
presence and severity of leukoaraiosis are independent predictors of dementia after stroke 
(Leys et al., 2005), but there are many potential confounders, such as cerebral atrophy, more 
frequent in patients with leukoaraiosis, lacunar infarcts, which share a common 
pathogenesis with leukoaraiosis, and stroke recurrence, which is more frequent in stroke 
patients with leukoaraiosis (Leys et al., 2005). Microbleeds are frequent in stroke patients 
and especially those with intracerebral arteriolopathies (Cordonnier et al., 2007) and in 
patients with VaD, and to a lower degree AD (Cordonnier et al., 2006). 
However, the question of their influence on the risk of post stroke dementia has never been 
systematically addressed. All these data confirm that the presence of previous brain injuries 
(vascular or neurodegenerative) is related to a higher risk to develop PSD, and their severity 
related to a more rapidly onset time. However, this “severity” may be not the NIHSS score 
or similar, but from one side the underlying “vessel disease” and from the other side the 
presence of subclinical neurodegenerative processes, or both, that is the overlap between 
AD and VaD, that is another intriguing issue influencing the time of onset of PSD. Vascular 
and degenerative dementias might be closer than previously thought, being dementia a 
spectrum which has only at the two extremities a “pure” degenerative type or a“pure” 
vascular one, while the majority of cases are definitely the results of different combinations 
of the two, always present. VaD and AD may thus be considered supplementary over the 
cognitive decline landscape. In conclusion, the debate about the vascular and 
neurodegenerative components of non-genetic AD is ongoing (Ivan et al., 2004). 
To solve the diagnostic dilemma “is “Alzheimer's dementia” Alzheimer's disease, vascular 
dementia, or both?” (Roman et al., 1993), the first much needed step is a revision of the 
current diagnostic criteria for vascular dementia, in which the description of mixed forms of 
dementia appear to be inadequate.  
2.1.6 The onset of Post Stroke Dementia according to time  
Individuals with PSD are patients in whom stroke is only the epiphenomenon of an 
underlying long-acting vascular disease. Accordingly, stroke patients younger than 45 years 
show very few instances of PSD. This long-acting vascular disorder, affecting in particular 
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the two inner layers of the vessel wall, may clinically occur with a wide range of clinical 
presentations. 
Nevertheless, the mechanism that determine these different patterns of disease are not yet 
completely understood. This heterogeneity in clinical expression is probably related to 
genetic differences between individuals. As a matter of fact, in patients suffering from 
stroke, PSD would be determined by an underlying chronic cerebrovascular disease. 
As a consequence, the time of onset of PSD would originate from the degree of severity of 
the abovementioned vascular disorder. In patients who have advanced chronic 
cerebrovascular disease, stroke would trigger the cognitive impairment and the time of 
onset of PSD will be extremely fast. On the other hand, in stroke patients with mild degree 
of “underlying” cerebrovascular disease, the risk of PSD will gradually increase over time, 
or be accelerated by the occurrence of subsequent single or multiple cerebrovascular events. 
In conclusion, with regard to vascular dementia and its various forms, it seems appropriate 
to say that the time of onset of PSD is closely linked to the severity of the impairment of the 
cerebral circulation. It has been shown that patients with global cerebral atrophy and MTLA 
may have pre-clinical AD clinically revealed by stroke (Leys et al., 2005).  
There are several other significant predictors of PSD that are not related directly to the 
stroke itself, including increasing age, female sex, low education, race (increased in blacks, 
Hispanics and south-east Asians, and lower in Caucasians and Chinese), and leukoaraiosis. 
Most of these factors are also associated with AD-LBD-FTD. This, along with the fact that 
pre-stroke cognitive decline increases the risk of PSD, suggests an interaction between pre-
existing degenerative pathology and stroke. 
Neuropathological studies confirm that patients with AD pathology and cerebrovascular 
disease have a greater severity of cognitive impairment than those with similar severity of 
either pathology. Indeed, such “mixed” pathology is more common than either pure 
vascular or degenerative pathology. Vascular mechanisms may be important in the 
development of AD-BLD-FTD pathology: vascular risk factors are risk factors for AD-BLD-
FTD also and cerebral hypoperfusion and microcirculatory changes may be a precursor of 
the neuropathological and clinical changes. In fact, it has been argued that there might be a 
pathogenic role of vascular disease in the basic phenomena of neuronal degeneration. The 
synthesis of these assumptions is called "Vascular Hypothesis of Alzheimer's disease" (de La 
Torre, 2011). According to this theory, AD would be primarily a vascular disease. Thus, 
"classical" cardiovascular risk factors would also be risk factors for AD, and neuronal 
degeneration would only be the result of an "energy crisis" of genetically predisposed 
neuronal populations. Several studies suggest that cerebral hypoperfusion is one of the 
earliest pathological signs in the development of cognitive failure (de la Torre, 2000). This 
phenomenon is more evident in the elderly, having already a dwindling cerebrovascular 
reserve due to advancing age. Other vascular risk factors may contribute to further decline 
in cerebral blood flow, resulting in unrelenting brain hypoperfusion. Brain hypoperfusion, 
in turn, can reach a critical threshold giving rise to a neuronal energy crisis via reduced ATP 
synthesis (Lassen et al., 1991). The ensuing metabolic energy crisis initially carves up 
ischemic-sensitive neurons in the hippocampus and posterior parietal cortex setting up 
cognitive meltdown and progressive neurodegenerative and later atrophic changes in the 






reactive oxygen species, aberrant protein synthesis, ionic membrane pump dysfunction, 
signal transduction impairment, neurotransmitter failure, abnormal processing of amyloid 
precursor protein resulting in beta-amyloid deposition and axonal microtubule disruption 
from tau hyperphosphorylation (de La Torre, 2002). Lenzi and Altieri investigated factors 
that might contribute to the development of delayed PSD and to the definition of its clinical 
presentation. 191 patients who were dementia-free 6 months after stroke were enrolled 
(Altieri et al., 2004). Dementia was diagnosed according to the ICD-10 criteria (Altieri et al., 
2004), while ethiologic diagnoses followed the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders 
Associations (NINCDS–ADRA) for AD (McKhann et al., 1984), and the NINDS–AIREN 
group for VaD (Altieri et al., 2004). About 21% of patients developed delayed PSD during 
the 4-year follow up. This finding confirmed data reported in previous studies showing that 
dementia is a frequent consequence of stroke and that the risk of dementia development, 
though higher in the very short period after stroke, remains important in the long term 
(Desmond et al., 1996 ; Desmond et al., 2000 ; Barba et al., 2004 ; Henon et al., 1997). Further, 
Lenzi and Altieri (Lenzi & Altieri, 2007) excluded patients with pre-stroke dementia, known 
to markedly increase the incidence of PSD (Barba et al., 2004; Henon et al., 1997). 
The clinical differentiation of delayed PSD yielded some intriguing results. Although the 
incidence of new cases of dementia was constant throughout the 4-year follow up, the 
cognitive pattern shifted from a predominant AD-BLD-FTD with cerebrovascular disease 
type in the first 2 years, and to a typical VaD type later on. 
In this view, the time interval between stroke and dementia onset might be crucial as a 
means of differentiating between its ethiopathological subtypes: PSD which develops up to 
15–20 months after stroke onset might present the clinical characteristics of the so-called 
“mixed dementia” arising from the unmasking effect of the vascular lesion on a previous 
degenerative process; subsequently, PSD may be due to the anatomical disruption of cortical 
relays and connections with other cortical or deeper structures, or to the cumulative effect of 
the new lesion which disrupts a previous functioning equilibrium (Tatemichi et al., 1990; 
Mungas et al., 2001 ; Mungas et al., 2002 ; Fein et al., 2000). 
Let us remember that functional studies have shown that vascular patients may compensate 
for cognitive impairments by increasing both the number and the regional perfusion of 
activated areas. This last mechanism seems to be less effective and may, consequently, 
become inadequate after a new vascular event (Di Piero et al., 2001). 
Both these mechanisms need a background of unimpaired neuronal network, and cannot be 
fully operative in presence of initial neurodegenerative processes. At present, is unclear if 
the interaction between stroke and degenerative pathology develop the unmasking previous 
degenerative changes, or whether there is a synergistic effect of stroke, perhaps through 
widespread synaptic or perfusional changes, that accelerates existing degenerative 
processes. 
We can intuitively conclude that the presence of an underlying AD-BLD-FTD can 
dramatically influence the time onset of PSD. Therefore, individuals with AD-BLD-FTD will 
develop PSD much faster than those without AD-BLD-FTD. This event will occur both if the 
AD-BLD-FTD neuropathological changes are already evident, or when stroke represents the 
triggering event of an undiagnosed pathological condition.  
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Until recently, the term vascular disease was considered synonymous of atherosclerosis. 
Nowadays, scientific evidences show that atherosclerosis and its acute and chronic 
consequences could be only one of the possible manifestations of a more complex vascular 
disorder. 
Probably, genetic differences allow the existence of a wide range of clinical expressions, in 
the context of a similar pathological process. First of all, we can recognize some individuals 
with a predominant “classical” vascular disorder; in these patients, the classical 
cardiovascular risk factors such as hypercholesterolemia, diabetes, hypertension and so on 
could lead to the genesis and development of the atherosclerotic plaque, which is the major 
target for the current strategies of prevention and treatment of the aterosclerothic disease. 
In fact, in the largest part of cases, the aim of the modern medicine is to decrease the 
prevalence and the incidence of the acute and chronic cardio-cerebro-vascular consequences 
of this pathological process. The cognitive impairment of these patients manifests as VaD. 
We can also recognize another group of patients without the aforementioned ”classical” 
vascular disorder. 
These individuals are probably affected by a silent but persistent vascular disease, which 
could similarly lead to dramatic consequences. In these individuals, cardiovascular risk 
factors don’t determine the development of atherosclerosis, but could cause a chronic brain 
hypoperfusion, responsible for the beginning and the progression of neuronal degeneration. 
The cognitive impairment of these patients manifests as AD-BLD-FTD. It could be 
speculated that vascular and degenerative dementias might be closer than previously 
thought, being dementia a spectrum which has only at the two extremities a “pure” 
degenerative type or a “pure” vascular one, while the majority of cases are definitely the 
results of different combinations of the two, always present. 
VaD and AD may thus be considered supplementary over the cognitive decline landscape. 
However, their borders show an extensive and variable representation. 
Nowadays, PSD is not considered as a specific entity requiring specific treatment. Patients 
with PSD are together patients with dementia and with stroke. Current guidelines for stroke 
prevention should be applied, but the specific issue of secondary prevention of stroke in 
patients with dementia (either pre-existing or new-onset dementia) is not addressed in any 
guidelines. 
It has been proposed that lowering of blood pressure could, in theory, reduce the incidence 
of cognitive decline because of reduction in stroke recurrence rates and indirect effects on 
the anticipation of the clinical onset of AD-BLD-FTD (Pasquier & Leys, 1997): accordingly 
several controlled trials showed a beneficial effect of lowering blood pressure on the risk of 
dementia (Tzourio et al., 2003; Forette et al., 1998). 
A symptomatic approach to dementia syndrome is necessary, depending on the presumed 
cause (AD-BLD-FTD, VaD or mixed). There have been no trials specifically done in PSD. 
However, both AD-BLD-FTD and VaD share a cholinergic deficit, and both disorders show 
some improvement when treated with cholinesterase inhibitors. Patients with AD-BLD-FTD 
and with vascular risk factors receive greater symptomatic benefits than patients with pure 






butyrilcholinesterase. The additional apparent benefits on disease progression detected in 
patients with hypertension and AD might be linked to drug effects on cerebrovascular 
factors. These findings could have an important effect on the way cholinesterase inhibitors 
are prescribed.  
In conclusion, the time of onset may be an important variable in the evaluation of patients 
with PSD. Currently, together with other conventional diagnostic techniques, it will provide 
us some useful details on the degree of cerebral impairment in the subject under 
examination. In addition, it is a very attractive starting point for research. For these reasons, 
the authors suggest to give more consideration at the time of onset in PSD evaluation 
criteria, in order to better stratify patients’ risk and to improve the state of knowledge 
regarding this dramatic pathology 
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